Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
1.250
-0.006 (-0.48%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.

The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.

The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.

Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings logo
Country United States
Founded 2005
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Bastiaan van der Baan

Contact Details

Address:
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
United States
Phone 631 830 7092
Website lixte.com

Stock Details

Ticker Symbol LIXT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001335105
CUSIP Number 539319202
ISIN Number US5393193017
Employer ID 20-2903526
SIC Code 2834

Key Executives

Name Position
Bastiaan van der Baan M.Sc. President, Chief Executive Officer and Chairman of the Board of Directors
Robert Neal Weingarten Chief Financial Officer, Vice President and Secretary
Johannes Henricus Matthias Schellens M.D., Ph.D. Consultant and Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 18, 2025 8-K Current Report
Apr 11, 2025 424B4 Prospectus
Apr 10, 2025 EFFECT Notice of Effectiveness
Apr 9, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 4, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Mar 31, 2025 8-K Current Report
Mar 27, 2025 8-K Current Report
Mar 24, 2025 10-K Annual Report
Mar 14, 2025 8-K Current Report
Mar 11, 2025 8-K Current Report